StockData
TG Therapeutics, Inc. logo

TG Therapeutics, Inc. (TGTX) stock

TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/303% above fair value
$62.71−0.05 (-0.08%)

Close on Nov 17, 2026Market cap $9.60BP/E 22.9Yield –

TG Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

TG Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was $136.45M, up 58.9% year over year. For fiscal 2025 it was $123.38M, up 193.8% from the year before. The highest annual figure on record is $123.38M in fiscal 2025.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025$123.38M+193.8%
FY2024Dec 31, 2024$42.00M+101.5%
FY2023Dec 31, 2023$20.84M–
FY2022Dec 31, 2022-$218.01M–
FY2021Dec 31, 2021-$344.49M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$21.73M-37.7%
Q1 FY2026Mar 31, 2026$34.83M+303.6%
Q4 FY2025Dec 31, 2025$50.52M+68.6%
Q3 FY2025Sep 30, 2025$29.38M+136.1%
Q2 FY2025Jun 30, 2025$34.86M+294.5%
Q1 FY2025Mar 31, 2025$8.63M–
Q4 FY2024Dec 31, 2024$29.96M–
Q3 FY2024Sep 30, 2024$12.45M-89.2%
Q2 FY2024Jun 30, 2024$8.84M–
Q1 FY2024Mar 31, 2024-$9.24M–
Q4 FY2023Dec 31, 2023-$12.45M–
Q3 FY2023Sep 30, 2023$114.86M–
Q2 FY2023Jun 30, 2023-$44.64M–
Q1 FY2023Mar 31, 2023-$36.92M–

More TG Therapeutics figures

See a number that looks wrong?